Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Haematologica|April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research NetworkChristina M Termini, Anna Moseley, Megan Othus, et al.
Blood Advances|July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemiaLori Muffly, Jun Yin, Sawyer Jacobson, et al.
Leukemia|March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplantCourtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Haematologica|April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research NetworkChristina M Termini, Anna Moseley, Megan Othus, et al.
Blood Advances|July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemiaLori Muffly, Jun Yin, Sawyer Jacobson, et al.
Leukemia|March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplantCourtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.
Pageof 17